reports
Microbix Reports Results for Q4 and Fiscal 2025
Microbix Reports Results for Q4 and Fiscal 2025 Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“2025” and “Q4”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program. Management DiscussionMicrobix added to both its capabilities ...
Microbix Schedules Release of Results for Q4 Fiscal 2025
Microbix Schedules Release of Results for Q4 Fiscal 2025 Results Release and Webinar Discussion on Morning of December 18, 2025 MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“Q4 2025”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to...
Microbix Launches New Products to Support H3N2 Flu Testing
Microbix Launches New Products to Support H3N2 Flu Testing Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs™ quality assessment products and availability of QUANTDx™ reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “Flu”). H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, wit...
Microbix Announces Initiation of Normal Course Issuer Bid
Microbix Announces Initiation of Normal Course Issuer Bid For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,346 Common Shares ("Shares"), that number being approximate...
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy Making HPV Tests & Quality Assessment Products Available across Mexico MISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Seegene Mexico S.A.P.I. de C.V. (Seegene Mexico), a firm focused upon transforming molecular diagnostics with innovative multiplex solutions, announce that Microbix external third-party quality assessment products (QAPs®) will be used to support the clinical use of ...
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests Supporting the Metrix® Molecular Point-of-Care Assay MISSISSAUGA, Ontario, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and SEKISUI Diagnostics, LLC (SEKISUI), a global manufacturer of innovative diagnostic tests, reagents, diagnostic systems, and raw materials, announce that Microbix external third-party quality assessment products (REDx™FLOQ® QAPs®) will be used to support SEKISUI’s U.S. commercialization of the...
Microbix Addresses Cybersecurity Incident
Microbix Addresses Cybersecurity Incident MISSISSAUGA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is addressing a cybersecurity incident relating to a ransomware attack that has had no impact on operations but involved the theft of data. Microbix is actively addressing the incident, which highlights the importance of the Company’s ongoing program to strengthen its cybersecurity. An international hacker group, responsible for hundreds of attacks on manufac...
Microbix Presenting at Muskoka Capital Event
Microbix Presenting at Muskoka Capital Event Meetings with Growth-Oriented Investors, September 26 to 28, 2025 MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025. Microbix’s CEO, Cameron Groome, and COO, Ken Hughes, will undertake a series of 18 ...
Microbix Assisting EMQN with Second Genetic-Test EQA Program
Microbix Assisting EMQN with Second Genetic-Test EQA Program Helping Ensure Appropriate Dosing of Widely-Used Anti-Clotting Drugs MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with fas...
Microbix Client Labquality Introduces Novel EQA Scheme at ESCV
Microbix Client Labquality Introduces Novel EQA Scheme at ESCV Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers MISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel external quality assessment (“EQA”) program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus (“HPV”). Labquality...
Microbix Hosts Ontario Minister Stephen Crawford
Microbix Hosts Ontario Minister Stephen Crawford Site Visit & Discussions at Biotech Manufacturing Facilities in Mississauga MISSISSAUGA, Ontario, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of Public and Business Service Delivery and Procurement, for a site visit to tour the company’s advanced biotechnology development and manufacturing facilities and discuss how next generation diagnostics can improve h...
Microbix Reports Results for Q3 Fiscal 2025
Microbix Reports Results for Q3 Fiscal 2025 Revenues of $3.5 million, Weaker Gross Margin, and Net Loss MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both Antigens and QAPs™, while YTD Antigens were up and QAPs were down YTD. Management DiscussionResults for Q3 were disappointing, impacted by two key events, cancellation of test-...
Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Relea...
Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Release and Webinar Discussion on Morning of August 14, 2025 MISSISSAUGA, Ontario, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2025 ended June 30, 2025 (“Q3 2025”) prior to the start of trading on August 14, 2025. At 10:00 AM ET that day, Microbix intends to hold a webi...
Microbix Launches QUANTDx™ Characterized Reference Materials
Microbix Launches QUANTDx™ Characterized Reference Materials New Product Line Supporting Diagnostic Assay Manufacturers MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays. QUANTDx is being launched at ADLM 2025, the conference of the Association for Diagnostic & Laboratory Medicine being held...
Microbix Exhibiting & Presenting at ADLM
Microbix Exhibiting & Presenting at ADLM Microbix & API Presenting H5N1 Pandemic Preparedness Results MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine (“ADLM”) conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infecti...
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
Microbix & Bulgaria’s NCIPD Execute Supply Agreement Microbix to Develop New Products using NCIPD Organism Collection MISSISSAUGA, Ontario and SOFIA, Bulgaria, July 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and the National Center for Infectious and Parasitic Diseases of Bulgaria (“NCIPD”), announce an agreement whereby NCIPD will supply a portfolio of pathogen seedstocks for production of Microbix quality assessment products (“QAPs™”). Following detailed discussions and a meeting ...
Microbix Attending & Presenting at Asia Pacific POC 2025
Microbix Attending & Presenting at Asia Pacific POC 2025 Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 (“POC 2025”). At POC 2025, Microbix will be presenting a poster of results about the global utility...
Microbix Reports Results for Q2 Fiscal 2025
Microbix Reports Results for Q2 Fiscal 2025 Revenues of $5.3 million, Improved Gross Margin, and Positive Net Income MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2025 ended March 31, 2025 (“Q2” and “H1”). Sales for Q2 and H1 reflected differential growth between Antigens (up) and QAPs™ (down), alongside a markedly-improved gross margin. Management DiscussionResults for H1 were largely satisfactory,...
Microbix & Aurevia Introduce Novel EQA Scheme
Microbix & Aurevia Introduce Novel EQA Scheme Pilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Aurevia Oy via its Labquality EQAS affiliate (Aurevia), announce a pilot external quality assessment (“EQA”) program to help clinical laboratories establish their proficiency at using molecular diagnostic methods (e.g., PCR tests) to diagnose bacterial vaginosis (“BV”). ...
Microbix Schedules Release of Results for Q2 Fiscal 2025
Microbix Schedules Release of Results for Q2 Fiscal 2025 Results Release and Webinar Discussion on Morning of May 15, 2025 MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix intends to hold a webi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.